Corporate Profile

Outlook Therapeutics is a biopharmaceutical company focused on the commercialization of LYTENAVA™ (bevacizumab-vikg), the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of neovascular (wet) age-related macular degeneration (AMD) in the United States. LYTENAVA™ (bevacizumab gamma) is also authorized in the European Union and the United Kingdom for the treatment of nAMD (wet AMD).

Building on the successful development of LYTENAVA, Outlook Therapeutics is advancing its mission to improve patient access to ophthalmic therapies and expand the potential of ophthalmic bevacizumab for retinal diseases. The Company's clinical development experience includes the NORSE ONE, NORSE TWO, NORSE THREE, and NORSE EIGHT clinical trials evaluating LYTENAVA for nAMD (wet AMD).

To support commercialization in the United States, Outlook Therapeutics has entered into a strategic commercialization agreement with Cencora to expand the Company's reach to retina specialists and their patients. Through this collaboration, Cencora provides third-party logistics (3PL), distribution, pharmacovigilance, and other commercial support services.